158 related articles for article (PubMed ID: 7555506)
1. Hormonal contraception in women with IDDM. Influence on glycometabolic control and lipoprotein metabolism.
Petersen KR; Skouby SO; Vedel P; Haaber AB
Diabetes Care; 1995 Jun; 18(6):800-6. PubMed ID: 7555506
[TBL] [Abstract][Full Text] [Related]
2. [Diabetes regulation and oral contraceptives. Lipoporotein metabolism in women with insulin dependent diabetes mellitus using oral contraceptives].
Petersen KR; Skouby SO; Jepsen PV; Haaber AB
Ugeskr Laeger; 1996 Apr; 158(17):2388-92. PubMed ID: 8685993
[TBL] [Abstract][Full Text] [Related]
3. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H
Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
[TBL] [Abstract][Full Text] [Related]
4. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
5. Contraception for women with diabetes: an update.
Skouby SO; Mølsted-Pedersen L; Petersen KR
Baillieres Clin Obstet Gynaecol; 1991 Jun; 5(2):493-503. PubMed ID: 1954724
[TBL] [Abstract][Full Text] [Related]
6. Oral contraceptives in diabetic women: metabolic effects of four compounds with different estrogen/progestogen profiles.
Skouby SO; Mølsted-Pedersen L; Kühl C; Bennet P
Fertil Steril; 1986 Nov; 46(5):858-64. PubMed ID: 3781003
[TBL] [Abstract][Full Text] [Related]
7. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel.
Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R
Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546
[TBL] [Abstract][Full Text] [Related]
8. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
Prasad RN; Liew D; Ratnam SS
Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
Petersen KR
Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
[TBL] [Abstract][Full Text] [Related]
10. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone.
Akerlund M; Almström E; Högstedt S; Nabrink M
Acta Obstet Gynecol Scand; 1994 Feb; 73(2):136-43. PubMed ID: 8116352
[TBL] [Abstract][Full Text] [Related]
11. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L
Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417
[TBL] [Abstract][Full Text] [Related]
12. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
[TBL] [Abstract][Full Text] [Related]
13. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
[TBL] [Abstract][Full Text] [Related]
14. Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptives.
Kuhl H; März W; Jung-Hoffmann C; Heidt F; Gross W
Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):363-9. PubMed ID: 2142576
[TBL] [Abstract][Full Text] [Related]
15. Fasting plasma lipids, lipoproteins and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives.
Oyelola OO
Contraception; 1993 May; 47(5):445-54. PubMed ID: 8513671
[TBL] [Abstract][Full Text] [Related]
16. Lipid metabolic studies in women with a polycystic ovary syndrome during treatment with a low-dose desogestrel-ethinylestradiol combination.
Cullberg G; Hamberger L; Mattsson LA; Mobacken H; Samsioe G
Acta Obstet Gynecol Scand; 1985; 64(3):203-7. PubMed ID: 3160212
[TBL] [Abstract][Full Text] [Related]
17. Plasma lipoproteins and apolipoproteins in insulin-dependent and young non-insulin-dependent Arab women.
al-Muhtaseb N; al-Yuosuf AR; Bajaj JS
Acta Diabetol Lat; 1991; 28(1):61-9. PubMed ID: 1862693
[TBL] [Abstract][Full Text] [Related]
18. Effects of contraceptive steroids on cardiovascular risk factors in women with insulin-dependent diabetes mellitus.
Petersen KR; Skouby SO; Sidelmann J; Mølsted-Pedersen L; Jespersen J
Am J Obstet Gynecol; 1994 Aug; 171(2):400-5. PubMed ID: 8059818
[TBL] [Abstract][Full Text] [Related]
19. Clinical and metabolic study of a new pill containing 20 mcg ethinylestradiol plus 0.150 mg desogestrel.
Fioretti P; Fruzzetti F; Navalesi R; Ricci C; Miccoli R; Cerri M; Orlandi MC; Melis GB
Contraception; 1987 Mar; 35(3):229-43. PubMed ID: 2956055
[TBL] [Abstract][Full Text] [Related]
20. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study.
Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C
Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
